In the April 2019 issue of the Journal of Thoracic Oncology, we reported cases of ALK-positive locally advanced NSCLC from two institutions in which neoadjuvant crizotinib showed quite acceptable efficacy and tolerability.1
Herein, we further describe the pathological evaluation and dynamic detection of circulating tumor DNA (ctDNA) in one patient receiving neoadjuvant crizotinib. Figure 1 summarizes the details of the entire therapeutic process. The patient is a 34-year-old male patient in whom lung adenocarcinoma and metastatic mediastinal lymph nodes were diagnosed and who received neoadjuvant crizotinib for 2 months. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.05.036
Authors: Chao Zhang, Yi-Long Wu, Wen-Zhao Zhong